A new review article in *Human Gene Therapy* summarizes the significant milestones in the development of gene therapy medicinal products that have facilitated the treatment of a significant number of rare diseases. The article also describes the challenges in the progress of gene therapy for rare diseases.

Juan Bueren, from Centro de Investigaciones Energéticas Medioambientales y Tecnológicas (CIEMAT), and President of the European Society for Gene and Cell Therapy (ESGCT); and Alberto Auricchio, from Telethon Institute of Genetics and Medicine (TIGEM), and Vice-President of the European Society for Gene and Cell Therapy, co-authored the article titled "Advances and Challenges in the Development of Gene Therapy Medicinal Products for Rare Diseases."

"Advances in the generation of integration competent vectors have markedly improved the efficacy and also the safety associated to ex vivo hematopoietic stem cell gene therapies during the last decade," state the authors. "In addition to ex vivo gene therapy, in vivo gene therapy has shown to be safe and effective therapy in humans. However, also some challenges remain to make this transformative therapeutic approach widely available."

"Professors Bueren and Auricchio, as the leaders of the ESGCT, provide a uniquely comprehensive perspective on the development of molecular therapies for rare diseases in Europe," says Editor in Chief Terence R. Flotte, MD, Celia and Isaac Haidak Professor of Medical Education and
Dean, Provost, and Executive Deputy Chancellor, University of Massachusetts Medical School.


Provided by Mary Ann Liebert, Inc


This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.